Finance Watch: Have Biopharma IPOs Hit Their Limit?

Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.

Finance Watch

Three biopharma firms were scheduled to launch initial public offerings during the week of 9-13 November but all three postponed or delayed their offerings, raising the question of whether the booming IPO market of 2020 finally has reached its limit. However, companies continue to join the IPO queue, suggesting there is still a market for some drug developers.

IN8bio, Inc. and Inhibikase Therapeutics, Inc. postponed their offerings and Compass Therapeutics Inc. withdrew its IPO plans...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business